Drug intelligence / Profile preview

SGN001

Development stage: Preclinical
Lead developer: Shenogen Pharma
Modality: Recombinant Proteins and Enzymes
Administration: Intratumoral, Intrabronchial

Overview

SGN001 is a novel recombinant protein developed by Shenogen Pharma, a Shanghai, China-headquartered biotech company. It is designed to target both immune checkpoints and angiogenesis, aiming for dual inhibition to enhance anti-tumor immunity and block vascular growth. This compound is intended for the treatment of cancer. Shenogen Pharma engaged ShangPharma for its preclinical and early clinical development, including assays, toxicology, and CMC, to accelerate its IND-enabling studies.

Targets

Checkpoint (Immune checkpoints)

Beyond the preview

Go deeper on SGN001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGN001.

Explore the full profile